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Summary 
Background 
The mcr-1 gene confers transferable colistin resistance. mcr-1-positive Enterobacteriaceae (MCRPE) 
have attracted substantial medical, media, and political attention; however, so far studies have not 
addressed their clinical impact. Herein, we report the prevalence of MCRPE in human infections and 
carriage, clinical associations of mcr-1-positive Escherichia coli (MCRPEC) infection, and risk factors for 
MCRPEC carriage. 
Methods 
We undertook this study at two hospitals in Zhejiang and Guangdong, China. We did a retrospective 
cross-sectional assessment of prevalence of MCRPE infection from isolates of Gram-negative bacteria 
collected at the hospitals from 2007 to 2015 (prevalence study). We did a retrospective case-control 
study of risk factors for infection and mortality after infection, using all MCRPEC from infection isolates 
and a random sample of mcr-1-negative E coli infections from the retrospective collection between 2012 
and 2015 (infection study). We also did a prospective case-control study to assess risk factors for 
carriage of MCRPEC in rectal swabs from inpatients with MCRPEC and mcr-1 negative at the hospitals 
and collected between May and December, 2015, compared with mcr-1-negative isolates from rectal 
swabs of inpatients (colonisation study). Strains were analysed for antibiotic resistance, plasmid typing, 
and transfer analysis, and strain relatedness. 
Findings 
We identified β1 6β1 non-duplicate isolates of Enterobacteriaceae, Acinetobacter spp, 
and Pseudomonas aeruginosa from 18 698 inpatients and β9βγ healthy volunteers. Of 17 498 isolates 
associated with infection, mcr-1 was detected in 76 (1%) of 5332 E coliisolates, 13 (<1%) of 
348 Klebsiella pneumoniae, one (<1%) of 890 Enterobacter cloacae, and one (1%) of 162 Enterobacter 
aerogenes. For the infection study, we included 76 mcr-1-positive clinical E coli isolates and 508 mcr-1-
negative isolates. Overall, MCRPEC infection was associated with male sex (209 [41%] vs 47 [63%], 
adjusted p=0·011), immunosuppression (30 [6%] vs 11 [15%], adjusted p=0·011), and antibiotic use, 
particularly carbapenems (45 [9%] vs 18 [24%], adjusted p=0·002) and fluoroquinolones (95 [19%] vs 23 
[30%], adjusted p=0·017), before hospital admission. For the colonisation study, we screened 2923 
rectal swabs from healthy volunteers, of which 19 were MCRPEC, and 1200 rectal swabs from patients, 
of which 35 were MCRPEC. Antibiotic use before hospital admission (p<0·0001) was associated with 
MCRPEC carriage in 35 patients compared with 378 patients with mcr-1-negative E coli colonisation, 
whereas living next to a farm was associated with mcr-1-negative E coli colonisation (p=0·03, univariate 
test). mcr-1 could be transferred between bacteria at high frequencies (10−1 to 10−γ), and plasmid types 
and MCRPEC multi-locus sequence types (MLSTs) were more variable in Guangdong than in Zhejiang 
and included the human pathogen ST131. MCRPEC also included 17 unreported ST clades. 
 
 
Introduction 
The relentless increase in multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria is worrying and has led to several global initiatives to unify national and international 
agenda to combat MDR and XDR infections.1,  2,  3,  4 Global awareness was precipitated by the rapid 
dissemination of carbapenem resistance mechanisms such as NDM-1, KPC, and OXA-48/181, and the 
realisation of the small number of antibiotics left to treat serious infections, such as colistin.5,  6,  7,  8 Until 
recently, colistin resistance was reported to be mediated by chromosomal mutations and possibly 
imposed a fitness cost to the organism.9,  10   Resistance to colistin is common in Klebsiella pneumoniae 
and Pseudomonas aeruginosa, but rare in Escherichia coli, and because of the complex mechanism 
involving lipopolysaccharide structures, the thought that this mechanism might become transferable was 
readily dismissed.11 
 
However, we reported the gene encoding the first transferable colistin resistance mechanism, 
termed mcr-1, in Enterobacteriaceae of both food-producing animal and human origins.12   Colistin has 
not yet been approved for use in human beings in China, but it has been used in animals as a 
therapeutic drug and feed additive since the early 1980s. Thus, we speculated that the emergence and 
spread of mcr-1 probably occurred first in animals and spread to human beings.12  Colistin will soon be 
made available in China for use in human beings for the treatment of infections caused by MDR Gram-
negative pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE). However, the 
coexistence of mcr-1 and carbapenem resistance genes, such as blaNDM-5/9 and blaKPC-2, identified in E 
coli from human infections and chicken meat, is of great concern, because the occurrence of the mcr-
1 gene in CRE would seriously compromise treatment options not only in China but also globally.13 
 
mcr-1-positive Enterobacteriaceae (MCRPE) have been reported across southeast Asia, north Africa, 
Europe, and North America. Hitherto, most of the bacteria carrying mcr-1 in human infections have been 
retrieved from historical studies with mcr-1 identified retrospectively from whole genome sequence 
data.14,  15  Furthermore, very few clinical reports have shown the effect of MCRPE on patient outcomes 
and these reports had very small sample sizes.16 
 
Although colistin is not yet used in clinical practice in China, it is commonly used as the last-line antibiotic 
in many countries, sometimes even for empirical treatment.8    In view of the increased reliance on colistin 
in the treatment of CRE and the intercontinental dissemination of mcr-1, the effect of the emergence of 
MCRPE in the clinical setting needs to be urgently addressed. We ascertained the prevalence of 
MCRPE, and the clinical associations and outcomes of mcr-1-positive E coli (MCRPEC) infections in 
patients in hospital from two provinces, Zhejiang and Guangdong. We also determine the prevalence of 
MCRPEC colonisation of patients in hospital and healthy volunteers and examine risk factors for carriage 
among patients. We have applied multi-locus sequence typing (MLST) analysis comparing MCRPEC 
and non-MCRPEC causing infections. 
  
Methods 
Study design and materials 
We undertook this epidemiological and clinical study at two geographically remote tertiary care hospitals 
in Zhejiang and Guangdong, China. Each hospital contains more than 3000 beds and serves mainly 
Hangzhou (catchment of 9 million people) and Guangzhou (catchment of 13·5 million people), the capital 
cities, as well as a wider catchment area for neighbouring cities in each province. 
 
First, we did a retrospective cross-sectional study to assess the prevalence and clinical characteristics of 
MCRPE (prevalence study). We included non-duplicate clinical isolates of Enterobacteriaceae, 
Acinetobacter spp, and Pseudomonas aeruginosa from inpatients collected between Jan 1, 2007, and 
April 30, 2015 (Fig 1), as part of a study of ȕ-lactam resistance. For the prevalence study, we included 
patients who had been admitted for 2 or more days at any units of the two hospitals and who had a 
sample taken more than 48 h after admission. We excluded patients with all forms of gastroenteritis and 
those with active bleeding from the rectum or anal fissures. The source of infection was determined as 
pneumonia, urinary tract infection, surgical site infection, intra-abdominal infection, line-related infection, 
or bacteraemia as defined by the US Centers for Disease Control and Prevention. 17 
 
Second, we did a retrospective case-control study to assess risk factors for infection and 30-day 
mortality after infection with MCRPEC (infection study; Fig 1). We included all MCRPEC identified in the 
prevalence study, and a sample of mcr-1-negative E coli infection (ten times the number of positive 
isolates) selected by a blinded random draw done by the investigators. For the random selection, we 
assigned a continuing number, which did not indicate any medical information, for all inpatients, followed 
with putting all the numbers into an electronic pool in a computer, and then selecting the numbers with a 
computer mouse. We included mcr-1-negative isolates collected between Jan 1, 2012, and April 30, 
2015, because no mcr-1-positive isolates were collected during 2007–11. 
 
We also did a prospective case-control study to assess risk factors for carriage of MCRPEC 
(colonisation study; Fig 1). We included isolates from rectal swabs collected at the hospitals and rectal 
swabs from healthy volunteers attending primary care practices for routine annual physical 
examinations, collected from May 1, to Dec 31, 2015, assessed using clinical microbiology. For the 
random selection, we used the method described previously for the infection study. We compared risk 
factors for MCRPEC carriage (mcr-1-positive cases from inpatients) with mcr-1-negative E coli isolates 
from inpatients selected by a blinded random draw (12 times the number of positive isolates). For the 
colonisation study, we included isolates from rectal samples collected within 24 h of admission to 
hospital for the inpatients who were admitted for more than 2 days, and samples collected within 12 h of 
physical examination for the healthy volunteers. We excluded neonates, pregnant women, patients or 
healthy volunteers with gastroenteritis, and patients with gastrointestinal cancer, gastrointestinal surgery, 
peptic ulcer, gastrointestinal bleeding, inflammatory bowel disease (eg, Crohn's disease, ulcerative 
colitis), intestinal polyps, intestinal fistula, anal fistula, or anal fissure. 
Ethical approval was given by The Second Affiliated Hospital of Zhejiang University and Sun Yat-Sen 
University Zhong Shan School of Medicine. Individual consent forms were translated into Mandarin and 
consent was obtained for all inpatients and healthy volunteers either face to face or by phone. We 
excluded patients from whom we could not obtain consent (eg, patient had moved or had died). All 
participants held the right to withdraw from the study at any stage. 
 
Procedures 
For analysis of risk factors during infection, we procured data from electronic medical records on patient 
demographics, underlying medical conditions, site of infection, intensive care unit (ICU) admission, 
presence of immunosuppressive factors (eg, AIDS, use of corticosteroids for more than 7 days), 
antibiotic use within 3 months before hospital admission or in hospital before isolation of pathogen, and 
clinical outcomes at 30 days. 
 
For the analysis of risk factors of colonisation study, we obtained patient demographics, ICU admission, 
residence, proximity to commercial animal farms, education and income, diets and drinking water, and 
antibiotic use before and during hospital admission from medical records and a survey questionnaire. To 
reduce the potential recall bias on the risk factor of proximity to commercial animal farms, we checked 
the location of home addresses with Google maps and Baidu maps to confirm proximity to farms. 
 
We initially identified all isolates from the retrospective collection (Fig 1) using Columbia blood agar 
(Oxoid, Hampshire, UK) with 5% sheep blood (Luqiao, Beijing, China), and identified species by MALDI-
TOF mass spectrometry (BrukerDaltonik GmbH, Bremen, Germany). Where the species could not be 
well interpreted by MALDI-TOF, we applied 16S rDNA sequencing. We screened isolates from rectal 
samples for the colonisation study by inoculating on Columbia blood agar. Only one suspected 
Enterobacteriaceae isolate was analysed per sample. To determine presence of MCRPE from rectal 
samples and all clinical isolates we assessed growth on media containing 2 mg/L of colistin. All isolates 
were subsequently screened for mcr-1 by PCR and sequencing.12 
 
We determined the plasmid or chromosomal location of mcr-1 gene in all MCRPEC isolates from both 
clinical and carriage isolates using the method previously described.12  We investigated the frequency of 
transfer of mcr-1-carrying plasmid in both the infection and colonisation E coli isolates by conjugation 
experiments using streptomycin-resistant E coli C600 or rifampicin-resistant E coliEC600 as the recipient 
strains, and transfer frequencies were calculated as the number of transconjugants per recipient. 
Antimicrobial susceptibility testing of all MCRPEC, as well as the mcr-1-negative E coli isolates used in 
the infection and colonisation studies, was done by agar dilution and interpreted according to European 
Committee on Antimicrobial Susceptibility Testing clinical breakpoints (version 6.0), and the Clinical and 
Laboratory Standards Institute document M100-S25.18 
 
Whole cell DNA of all MCRPEC was prepared with the Wizard Genomic DNA Purification Kit (Promega, 
Beijing, China), submitted to whole genome sequencing,18  and a draft assembly of the sequences was 
done with the CLC Genomics Workbench 8.5 (CLC Bio, Aarhus, Denmark). MLST, Mob typing, and Inc 
typing of mcr-1-positive isolates of both wild-type and transconjugants were done by searching the 
assembled contigs of the recognised chromosomal or plasmid sequences, and by specific PCR 
assays as needed. Sequence types (STs) and corresponding MLST gene allele profiles were entered 
into BioNumerics (Applied Maths, Belgium). The BURST algorithm was used to relate STs between 
various criteria of geographical location and clinical history. 
 
Statistical analysis 
Clinical data were collected and collated into specifically designed databases within Microsoft Excel 
2013 and Minitab17 statistical software. Databases were password protected throughout the course of 
the study. We calculated risk factors for mcr-1-positive E coliinfection and colonisation using a two-stage 
approach. We used univariate statistical tests to assess key risk factors for potential association. Those 
significant at the 10% level were entered into multivariable logistic regression using IBM SPSS software. 
Separate models were fitted for overall antibiotic use and exploration of the effect of individual classes of 
antibiotics. Given the categorical nature of the variables, binary data were tested by χ2 analysis or 
Fisher's exact test. Continuous data were tested with the Mann-Whitney U test. 
 
Role of the funding source 
The funder had no role in the study design, data collection, data analysis, data interpretation, or writing 
of the report. The corresponding authors had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
 
  
Results 
Prevalence of mcr-1 
For the prevalence study, we analysed 17 498 isolates from 18 698 inpatients, including 10 688 
Enterobacteriaceae, 3549 Acinetobacter spp, and 3261 P aeruginosa (Fig 1). We detected mcr-1 in 76 
(1%) of 5332 E coli, 13 (<1%) of 3480 K pneumoniae, one (<1%) of 890 E cloacae, and one (1%) of 
162 Enterobacter aerogenes. Over the sampling period, we noted a general increase in the prevalence 
of mcr-1-positive E coli in both hospitals.  A non-linear increase in mcr-1- positive K pneumoniae was 
also noted. 
 
For the colonisation study, we analysed rectal swabs of 1200 inpatients and 2923 healthy volunteers, 
from which we identified 4123 Enterobacteriaceae. 35 (3%) of 1199 E coli isolates from inpatients were 
positive for mcr-1, and one of one E cloacae isolate from inpatients was positive; 19 (1%) of 2923 E 
coli isolates from healthy volunteers were positive for mcr-1. 
 
Minimum inhibitory concentration (MIC) profiles of MCRPEC and mcr-1-negative E coli isolates 
In the infection study, resistance was significantly more common in E coli isolates with mcr-1 (n=76) than 
in those without mcr-1(n=508) for most antimicrobial drugs tested, including not only colistin and 
polymyxin B, but also amoxicillin plus clavulanic acid, cefotaxime, ceftazidime, cefepime, gentamicin, 
amikacin, ertapenem, fosfomycin, nitrofurantoin, and ciprofloxacin (Table 1). 
 
There were large differences in MIC50 between MCRPEC isolates from inpatients with infections (n=76) 
and those from rectal swabs in healthy people (n=19), with differences of more than 32-fold for ampicillin, 
512-fold for cefotaxime, 64-fold for ceftazidime, 64-fold for cefepime, and 64-fold for ciprofloxacin. 
However, the MIC50 values from clinical E coli isolates from inpatients with infections (n=76) were similar 
to the isolates from rectal swabs from inpatients (n=35), except for ceftazidime, cefepime, and 
ciprofloxacin, which were eight-fold, 32-fold and 16-fold higher, respectively. 
 
Coexistence of mcr-1 and carbapenem resistance 
Among all 146 MCRPE (91 from the retrospective collection and 55 from the colonisation collection), 
five E coli isolates from clinical samples were carbapenem resistant: three from Zhejiang and two from 
Guangdong. All five isolates were resistant to ertapenem, with MICs of 4 mg/L (n=2), 8 mg/L (n=2), and 
64 mg/L (n=1), whereas only one isolate (ZJ487 from an intra-abdominal fluid sample in Zhejiang) was 
resistant to imipenem (>256 mg/L) and had intermediate resistance to meropenem (4 mg/L); the other 
four isolates were susceptible to both imipenem and meropenem. Four of these five inpatients with CRE 
recovered after treatment, with only one inpatient from Guangdong without improvement. Screening for 
carbapenem resistance genes among the five carbapenem-resistant E coli harbouring mcr-1 showed 
that two isolates, the ZJ487 with ST90 from intra-abdominal fluid of an inpatient from Zhejiang and GD50 
with ST744 from a faecal sample of a healthy volunteer from Guangdong, were blaNDM-1-positive. Further 
analysis showed that blaNDM-1 and mcr-1 were located on the chromosome and on plasmids of these 
isolates, respectively. In addition to blaNDM-1, isolate ZJ487 carried blaTEM-1, blaSHV-12, blaCTX-M-55, 
and blaOXA-1 and isolate GD50 carried blaTEM-1, blaSHV-12, blaCTX-M-14, and blaCTX-M-15. The other three 
isolates were negative for carbapenemase genes but were extended-spectrum ȕ-lactamase-positive 
(eg, blaCTX-M-15 in two isolates and blaCTX-M-55 in another). 
 
Risk factors 
For the infection study, we collected clinical data from 76 mcr-1-positive isolates and randomly selected 
760 mcr-1-negative clinical E coli isolates (of which 252 were excluded because of incomplete data, 
leaving 508) from 4609 E coli infection cases. 30-day mortality was 7·3% for mcr-1-negative infections 
and 11·8% for mcr-1-positive infections. Being male, immunosuppressed, or having received antibiotics 
in the past 3 months were significant risk factors for mcr-1-positive infection (Table 2). Use of 
carbapenems and fluoroquinolones in the previous 3 months was particularly associated with increased 
risk. Patient age was not associated with mcr-1-positivity (Table 2). We saw no association with 
either mcr-1-positive or mcr-1-negative infections in patients with neutropenia or undergoing artificial 
lung ventilation (Table 2). With only two regions (Guangdong and Zhejiang), we analysed region as a 
fixed effect and it was no longer significant in the multivariable model (Table 2). 
 
In the colonisation study, we identified 35 MCRPEC isolates from rectal swabs of inpatients. We 
randomly selected 420 mcr-1-negative isolates from inpatients for comparison, of which 42 were 
excluded because of incomplete data, leaving 378 isolates of mcr-1-negative E coli (Fig 1; Table 3). 
Antibiotic use before hospital admission was a major risk factor for colonisation by mcr-1-positive E 
coli (unadjusted p=0·0008; adjusted p<0·0001). Living in proximity to livestock was a risk factor for 
colonisation by mcr-1-negative E coli in the unadjusted analysis (p=0·03) but not in the adjusted analysis 
(p=0·995; Table 3). 
 
In addition, we analysed all associations and outcomes for both mcr-1-negative E coli and MCRPEC 
comparing Guangdong with Zhejiang. Significant differences were noted in several social aspects 
between the two regions, including living place, education, income, diet, and drinking water. 
 
High frequency of transfer of mcr-1 carrying plasmids 
S1-pulsed field gel electrophoresis and Southern blotting of 130 MCRPEC (76 from the infection study 
and 54 [one isolate had lost the plasmid during this stage of the analysis and could not be included in 
these data] from the colonisation study) showed that mcr-1 was located on plasmids with sizes ranging 
from 32 kb to 400 kb in 123 isolates, and on the chromosome in seven isolates Among the 123 isolates 
carrying mcr-1 on plasmids, mcr-1 was successfully transferred to E coli EC600 or C600 on 42 (34%) 
occasions. Frequency of transfer differed substantially, ranging from 10−1 to 10−10, while 29 (69%) of 
these 42 isolates had high conjugation rates   Two main markers (Inc and Mob) of mcr-1-carrying 
plasmids in the transconjugants were characterised. IncX4 and IncI2 were the most prevalent Inc types 
identified in 13 and 14 transconjugants, respectively. Other Inc types included F (n=7), K (n=6), FIB 
(n=6), I1-1Ȗ (n=6), N (n=4), and FIIS (n=1). 11 transconjugants were non-typeable using the current Inc 
classification. Mob typing showed that P51 and F12 were found in 11 and nine transconjugants, 
respectively. Both H121 and Qu were found in one transconjugant, but 24 transconjugants could not be 
typed using the Mob system. 
 
Diversity of MCRPEC strains 
We assessed clonality and clades of both mcr-1-negative and mcr-1-positive E coli strains from the 
infection study (Fig 1) as minimum spanning trees for Guangdong (Fig 2A) and Zhejiang (Fig 2B). Both 
the number and diversity of strains enrolled from Guangdong were greater than those from Zhejiang, 
with Guangdong having 21 ST clades representing five or more E coli compared with eight STs from 
Zhejiang. From these clades, mcr-1-positive E coli were found in ST602, ST101, ST410, ST95, ST1193, 
ST354, ST156, ST10, ST117, ST405, ST131, and ST457 from Guangdong compared with ST410, 
ST617, ST10, ST648, and ST354 form Zhejiang (Fig 2). Overall, our data suggest substantial horizontal 
dissemination of mcr-1 through E coli populations; mcr-1 was found in 30 (26%) of 116 ST clades from 
Guangdong and 25 (34%) of 73 ST clades from Zhejiang. Many of these ST clades were large, including 
ST131, ST95, ST1193, and ST405 from Guangdong. mcr-1 was not found in substantial E coli clades 
such as ST69, ST648, and ST38. By contrast with Guangdong, mcr-1 was not identified in the clades 
ST131, ST1193, or ST405 in Zhejiang. Across all tested samples, we discovered isolates in 17 new 
distinct STs carrying mcr-1. 
 
The clades identified among the carriage isolates (both hospital and community) from the colonisation 
study were diverse from both Zhejiang and Guangdong with some commonality in the clades isolated 
from clinical samples—eg, ST10, ST156, ST117, and ST131 (Fig 3). However, ST48, ST4014, and ST58 
were not isolated clinically (Fig 3). 
  
Discussion 
MCRPE gained global attention after our finding of the mobile colistin resistance mechanism MCR-1.12  
Following our report of emergence of MCR-1 in both animals and human beings, we undertook a 
comprehensive study on the prevalence, clinical association, and carriage of MCRPE in human beings. 
Analysis of the different associations and outcomes from all infections (mcr-1-negative and MCRPEC) 
showed one unexpected result. There was a gender bias (p=0·011) in whether the infection was mcr-
1positive with a male:female ratio of 41:59 for mcr-1 negative Enterobacteriaceae and 63:37 for 
MCRPEC infections. Unsurprisingly, previous antibiotic exposure was strongly associated with the 
presence of mcr-1-positive infection. In view of the potential of mcr-1to coexist with other resistance 
genes on the same plasmids, coselection of mcr-1 with other antibiotics, regardless of the use of colistin 
in human beings in China, is a likely scenario. Our first study of MCRPE showed close association with 
animals and husbandry practices and thus we anticipated a positive association with close proximity to 
farms.12  Counterintuitively, however, we observed a weak association for MCRPEC carriage with living 
distantly from farms. 
 
MLST analysis shows the extreme divergence of E coli strains carrying mcr-1 not only between Zhejiang 
and Guangdong, but also within each hospital. MCRPEC could be divided into 30 different clades from 
Guangdong and 25 from Zhejiang, in most cases these involved only one representative isolate. Of 
these mcr-1-positive clades, only ST10, ST410, and ST354 were common to both regions. The diversity 
of strains carrying mcr-1 is further shown by the fact that 17 isolates belonged to new or unreported 
MLST groups. The high level of heterogeneity is supported by our data showing high transmission rates 
of mcr-1-carrying plasmids into laboratory recipients (transconjugants), with the dominant Inc type being 
IncX4 that has been previously reported in blaCTX-M-carrying E colifrom both human beings and food 
animals in Hong Kong, China.19   66% of isolates carrying plasmid-borne mcr-1 could not be transferred 
into recipient E coli isolates, although increased transfer frequencies were observed in some other E 
coli isolates from this study. Although Guangdong and Zhejiang have common mcr-1-positive ST groups, 
these E coli clades have different plasmid backbones, suggesting independent acquisition of mcr-1 by 
these STs. 
E coli ST156 belongs to phylogenetic group A and is generally not considered to be highly virulent, 
although a recent study from Spain would suggest otherwise.20   ST156 has been previously reported 
from China and associated with MDR and XDR phenotypes, but mainly from poultry.21,  22  E coli ST101 
is widely regarded as having environmental lineage and being associated with water and sewerage, and 
also poultry; however, it has been associated with carbapenem resistance and XDR clinical 
outbreaks.22,  23  To the best of our knowledge, this study is the first report of E coli ST101 in mainland 
China. E coli ST95 is now thought to be more pathogenic than are ST156 and ST101 and considered a 
human and avian pathogen.24  E coli ST10 has only previously been reported from animals in China and 
thus this is the first report of ST10 from human infections in China.25  ST131 has long been recognised 
as the virulent global epidemic strain associated with human disease and also displaying MDR and XDR 
phenotypes.26   Until now, the only ST131 isolate reported carrying mcr-1 was from chicken meat 
imported into Denmark.27   In this study, we describe three ST131 mcr-1-positive isolates from 
Guangdong that would suggest colistin resistance might be associated with poorer clinical outcome than 
other STs. Chinese reports on patient infections suggest that E coli ST131 is prevalent28 and thus, the 
probability of mcr-1plasmids further being disseminated among these pathogenic E coli seem highly 
likely. However, in this study, the patients infected with mcr-1-positive E coli ST131 causing skin and soft 
tissue, bloodstream, and urinary tract infections recovered, suggesting that in this limited sample mcr-1-
positive E coli ST131 strains were not pathogenic. Some clades only found in carriage isolates—eg, 
ST48, ST4014, and ST58—were not isolated clinically, suggesting they could be less likely to cause 
disease. 
 
We acknowledge several limitations in our study. First, although we noted significant increases of mcr-1-
harbouring clinical isolates during 2012–15 compared with 2007–11, these were from retrospective data 
taken from samples in 2012–15. The possibility of loss of mcr-1-carrying plasmids during storage cannot 
be excluded, and so the prevalence of mcr-1 and numbers of colistin resistance phenotypes from these 
retrospectively collected isolates might be underestimated. Second, we only included 378 (33%) of 
1164 mcr-1-negative colonisation isolates and 508 (11%) of 4533 mcr-1- negative infection isolates for 
MLST. Analysis of more isolates for MLST would provide a more compelling database and a greater 
case for strain relatedness between isolates. Third, we have noted differences between Guangdong and 
Zhejiang provinces, but cannot further speculate as to why these differences have occurred without more 
in-depth observations and analysis and they might not be generalisable across other provinces and all of 
China. Last, the risk factors that were reported by the patients and the volunteers might be confounded 
by recall bias. 
 
Although there have been many reports of carbapenem resistance in Chinese hospitals, most MCRPEC 
were carbapenem-susceptible; however, in this study, resistance to ciprofloxacin, cefotaxime, and 
cefepime was especially common. These results suggest that MCRPEC were able to recruit other 
resistance genes and become multiply drug-resistant, which could raise difficulties in the treatment of 
patients with clinical infection due to MCRPEC. Despite the fact that almost all MCRPEC were colistin-
resistant, clinical colistin resistance in China is somewhat of an enigma because colistin is not generally 
used in human beings. The first report of mcr-1 in China resulted in substantial policy discussions and 
has encouraged the withdrawal of colistin.29    In part, this report is likely to advocate the use of colistin in 
Chinese patients and its subsequent withdrawal from the farming sector. Accordingly, this study provides 
a useful baseline of colistin resistance to monitor the effect of its introduction and provide predictive 
outcomes on treatment failures. 
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Table 1 
Minimum inhibitory concentration profiles of clinical infection-derived Escherichia coli with 
or without mcr-1 
 
 mcr-1-negative E coli 
(n=508) 
mcr-1-positive E 
coli (n=76) 
p value 
Colistin  53/455 (10%)  74/2 (97%)  <0·0001  
Polymyxin B  117/391 (23%)  74/2 (97%)  <0·0001  
Tigecycline  24/467 (5%)  1/71 (1%)  0·178  
Ampicillin  442/66 (87%)  72/4 (95%)  0·053  
Amoxicillin plus 
clavulanic acid  
125/383 (25%)  45/31 (59%)  0·0005  
Cefotaxime  292/200 (58%)  64/10 (84%)  0·0005  
Ceftazidime  172/260 (34%)  41/24 (54%)  0·0008  
Cefepime  185/219 (36%)  43/21 (57%)  0·001  
Gentamicin  227/277 (45%)  46/25 (61%)  0·002  
Amikacin  12/490 (2%)  14/60 (18%)  <0·0001  
Ertapenem  12/490 (2%)  5/70 (7%)  0·041  
Imipenem  4/504 (1%)  1/75 (1%)  0·641  
Meropenem  1/501 (<1%)  0/75  0·699  
Fosfomycin  182/326 (36%)  45/31 (59%)  0·0008  
Nitrofurantoin  11/497 (2%)  7/69 (9%)  0·0009  
Ciprofloxacin  313/175 (62%)  62/11 (82%)  0·0005  
 
Data are number resistant/number sensitive (% of resistance rates). p value for comparisons 
of the resistance rates of mcr-1-positive and mcr-1-negative groups.  
 
Table 2  
Risk factors and associated outcomes of mcr-1-positive Escherichia coli infection 
 
mcr-1-negative E 
coli (n=508) 
mcr-1-positive E 
coli (n=76) Unadjusted p value * Adjusted p value † 
Adjusted p 
value ‡ 
Region 
  0·006 0·208 0·044 
Guangdong 348 (90%) 40 (10%)    
Zhejiang 160 (82%) 36 (18%)    
 
  
   
Age (years) 54·7 (18·17) 56·2 (17·85) 0·485   
 
  
   
Sex (male) 209 (41%) 47 (63%) 001 0·010 0·011 
 
  
   
Site of infection   0·074 0·513 0·513 
Respiratory 54 (11%) 16 (21%)    
Bloodstream 73 (14%) 8 (11%)    
Skin and soft tissue 37 (7%) 8 (11%)    
Intra-abdominal 141 (28%) 22 (29%)    
Urinary tract 199 (39%) 22 (29%)    
Bone or joint 0 0    
CNS 4 (1%) 0    
 
  
   
Admitted to ward (intensive care unit) 38 (8%) 8 (11%) 0·358   
 
  
   
Comorbidities and risk factors      
Immunosuppression 30 (6%) 11 (15%) 0·006 0·011 0·011 
Diabetes 80 (16%) 9 (12%) 0·377 .. .. 
Neutropenia 11 (2%) 1 (1%) 1·000 .. .. 
Artificial lung ventilation 18 (4%) 2 (3%) 1·000 .. .. 
Vascular catheter 131 (26%) 22 (29%) 0·559 .. .. 
Abdominal or pelvic catheter 40 (8%) 2 (3%) 0·099 0·096 0·114 
Urinary catheter 128 (25%) 24 (32%) 0·237 .. .. 
Antibiotic use in the past 3 months 405 (80%) 74 (97%) 0·0009 0·008 .. 
Type of antibiotic used in the past 3 months      
Penicillin and ȕ-lactamase inhibitor combination 102 (20%) 23 (30%) 0·043  0·559 
Cephalosporin (narrow) 20 (4%) 4 (5%) 0·538  .. 
Cephalosporin (broad) 127 (25%) 23 (30%) 0·327  .. 
Carbapenem 45 (9%) 18 (24%) 0·0001  0·002 
Aminoglycosides 21 (4%) 3 (4%) 1·000  .. 
Fluoroquinolones 95 (19%) 23 (30%) 0·019  0·017 
 
Data are mean (SD) or n (%). *Univariate tests: everything significant at 10% level selected for multivariable models. †Model including: region, site of 
infection, sex, immunosuppression, abdominal or pelvic catheter, and antibiotic use in the past 3 months. ‡Model including: region, site of infection, 
sex, immunosuppression, abdominal or pelvic catheter, and use in the past γ months of penicillins and ȕ-lacatamase inhibitors, carbapenems, and 
fluoroquinolones
Table 3 
Risk factors associated with mcr-1-positive Escherichia coli colonisation in patients in hospital 
 
 
mcr-1-negative E 
coli (n=378) 
mcr-1-
positive E 
coli (n=35) 
Unadjusted p 
value * 
Adjusted 
p value † 
Region   0·19  
Guangdong 128 (34%) 8 (23%)   
Zhejiang 250 (66%) 27 (77%)   
     
Age (years) 60 (10–82) 55 (27–89) 0·92  
     
Sex     
Male 197 (52%) 21 (60%) 0·37  
Female 181 (48%) 14 (40%) ..  
     
Admitting ward     
Non-intensive care unit 332 (88%) 31 (89%) 0·89 .. 
Intensive care unit 46 (12%) 4 (11%) .. .. 
     
Living place     
City/county 216 (57%) 17 (49%) 0·33 .. 
Village 162 (43%) 18 (51%) .. .. 
     
Proximity to commercial 
animal farm 
    
<1 km 142 (38%) 10 (29%) 0·03 0·995 
1–10 km 62 (16%) 12 (34%) .. .. 
>10 km 174 (46%) 13 (37%) .. .. 
     
Education     
None/primary 166 (43·9%) 22 (63%) 0·09 0·052 
Secondary 147 (38·9%) 9 (26%) .. .. 
Tertiary 65 (17·2%) 4 (11%) .. .. 
     
Income class     
Low 166 (44%) 20 (57%) 0·13 .. 
Middle/high 212 (56%) 15 (43%) .. .. 
     
Diets     
Vegetarian 11 (3%) 0 (0%) 0·61 .. 
Non-vegetarian 367 (97%) 35 (100%) .. .. 
     
Antibiotic use before hospital 
stay 
    
Yes 88 (23%) 20 (57%) 0·0008 <0·0001 
No 243 (64%) 15 (43%) .. .. 
Not sure 47 (12%) 0 .. .. 
     
Antibiotic use during hospital 
stay ‡ 
    
Yes 318 (84%) 32 (91%) 0·25 .. 
No 60 (16%) 3 (9%) .. .. 
     
Drinking water     
Municipal 316 (84%) 30 (86%) 0·75 .. 
Non-municipal (vendor, well, 
or other) 62 (16%) 5 (14%) .. .. 
 
Data are median (IQR) or n (%). *Univariate tests. All those testing at p<0·05 were deemed significant. All those 
testing at a 10% significance level were selected for multivariable analysis. †Multivariable model includes 
proximity to commercial animal farms, education, and antibiotic use before hospital admission. ‡Before E coli 
isolation. 
 
 
Figure 1 
 
Flowchart diagram of samples collection in two hospitals in Zhejiang and Guangdong provinces 
 
 
 
 
P aeruginosa=Pseudomonas aeruginosa. E coli=Escherichia coli. K pneumoniae=Klebsiella 
pneumoniae. E cloacae=Enterobacter cloacae. E aerogenes=Enterobacter aerogenes. S 
marcescens=Serratia marcescens. MCRPEC=mcr-1-positive Escherichia coli.      . 
 
 
  
Figure 2 
Minimum spanning trees of mcr-1-positive Escherichia coli by MLST type and gene allele profile 
for Guangdong (A) and Zhejiang (B) 
 
 
Each node within the tree represents a single ST. The size of the nodes is proportional to the 
number of isolates represented by said node. Length of branches between each node is 
proportional to the number of different alleles (out of seven MLST genes) that differ between two 
linked nodes/ST. Selected nodes are labelled with corresponding ST, phylogenetic group, and 
number of isolates represented. New STs identified are in blue. MLST=multi-locus sequence 
typing. ST=sequence type 
  
Figure 3 
Minimum spanning tree of mcr-1-positive Escherichia coli by MLST type and gene allele from 
colonised patients from hospitals and colonised healthy volunteers 
 
 
 
Each node within the tree represents a single ST. The size of the nodes is proportional to the 
number of isolates represented by said node. Length of branches between each node represents 
the number of different alleles (out of seven MLST genes) that differ between two linked nodes/ST. 
Selected nodes are labelled with corresponding ST, phylogenetic group, and number of isolates 
represented. New STs identified with the blue border. MLST=multilocus sequence typing. 
ST=sequence type. 
 
